SAN FRANCISCO, CALIFORNIA — February 17, 2026 — Leads & Copy — GT Biopharma, Inc. (NASDAQ: GTBP) announced that Michael Breen, Executive Chairman and Chief Executive Officer, will participate in the Centurion One Capital 9th Annual Toronto Growth Conference on March 5th, 2026, in Toronto, Ontario.
The company will be available for one-on-one meetings at the conference. Those interested can contact their Centurion One Capital representative.
The conference will be held on March 5th, 2026, from 8:00 AM EDT – 5:00 PM EDT, and will feature presentations, panel discussions, and investor meetings.
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing immuno-oncology therapeutic products based on its proprietary TriKE® NK cell engager platform. The TriKE® platform is designed to enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology.
TriKE® is a registered trademark owned by GT Biopharma, Inc.
Source: GT Biopharma
